Bio-Gene Technology (ASX:BGT) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Bio-Gene Technology Debt-to-Equity?

Bio-Gene Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Bio-Gene Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Bio-Gene Technology's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$3.69 Mil. Bio-Gene Technology's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bio-Gene Technology's Debt-to-Equity or its related term are showing as below:

ASX:BGT's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Bio-Gene Technology Debt-to-Equity Historical Data

The historical data trend for Bio-Gene Technology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Gene Technology Debt-to-Equity Chart

Bio-Gene Technology Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

Bio-Gene Technology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Bio-Gene Technology's Debt-to-Equity

For the Biotechnology subindustry, Bio-Gene Technology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gene Technology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's Debt-to-Equity falls into.

Bio-Gene Technology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bio-Gene Technology's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.221
	=	0.00

Bio-Gene Technology's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.691
	=	0.00

Bio-Gene Technology (ASX:BGT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bio-Gene Technology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bio-Gene Technology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Gene Technology (ASX:BGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Gene Technology Ltd (ASX:BGT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000

Website

https://www.bio-gene.com.au

Bio-Gene Technology Ltd is an Australian biotechnology company engaged in the development and commercialization of insecticide products. It develops a patent-protected product platform based on a naturally occurring class of chemicals known as beta-triketones. Its product includes Qcide and Flavocid. Its target applications include agriculture, public health, and consumer and animal health. The firm operates in one business segment namely the conduct of research and development activities in the discovery of novel insecticides.

Bio-Gene Technology (ASX:BGT) Headlines

From GuruFocus

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

By Business Wire Business Wire • 12-20-2021